Osteosarcoma Market Expansion in 7MM from 2025-2034 Due to Novel Treatments and Tech Advancements | DelveInsight (Paraphrased)
The osteosarcoma market is set to grow substantially over the next two decades, driven by the development of innovative treatments and increased clinical and commercial activities aimed at improving patient outcomes in major developed markets.
According to a comprehensive report by DelveInsight, the total incident population of osteosarcoma in the 7MM (United States, EU4, and Japan) was over 2K in 2024. The United States holds the largest market share in osteosarcoma treatment within the 7MM, accounting for the highest treatment market size in 2024.
Key trends in the osteosarcoma market include the introduction of novel therapies such as HALMB-0168 by AlaMab Therapeutics in collaboration with CSPC Pharmaceutical, Naxitamab 15-096 by Y-mAbs Therapeutics, and OST-HER2 (OST31-154) by OS Therapies. These innovations are expected to transform treatment dynamics, supported by increasing awareness among healthcare providers and caregivers.
OS Therapies plans to submit a Biologics License Application (BLA) to the US FDA for OST-HER2 in osteosarcoma by 2025. Around 80% of all subtype-specific cases were of conventional osteosarcoma in 2024. However, challenges remain, with around half of osteosarcoma patients exhibiting or developing chemotherapy resistance during treatment.
The lack of approved drugs for chemo-resistant disease and maintenance therapy presents opportunities for pharmaceutical companies to enter the osteosarcoma market. The Osteosarcoma Market Report, published by DelveInsight, covers the study period 2020-2034 in the 7MM and includes related reports on Osteosarcoma Pipeline, Ewing Sarcoma Market, Soft Tissue Sarcoma Market, and Chondrosarcoma Market.
The report is divided into 16 sections, including Osteosarcoma Market Key Insights, Osteosarcoma Market Report Introduction, Osteosarcoma Market Overview at a Glance, Osteosarcoma Market Executive Summary, Disease Background and Overview, Osteosarcoma Treatment and Management, Osteosarcoma Epidemiology and Patient Population, Patient Journey, Osteosarcoma Marketed Drugs, Osteosarcoma Emerging Drugs, Seven Major Osteosarcoma Market Analysis, Osteosarcoma Market Outlook, Potential of Current and Emerging Therapies, KOL Views, Unmet Needs, SWOT Analysis.
The report segments the data into Total Incident Cases, Site-specific Cases, Sub-types Specific Cases, Stage-specific Cases, Age-specific Cases, and Gender-specific Cases. Key therapies included in the report are HS-20093, OST-HER2, Vactosertib, DANYELZA, Surufatinib, ALMB-0168, MEPACT, and others. Key companies mentioned in the report are Hansoh Pharmaceutical, OS Therapies, Y-mAbs Therapeutics, Hutchmed, MedPacto, AlaMab Therapeutics, CSPC Pharmaceutical, Takeda, and others.
The osteosarcoma market dynamics are expected to change due to extensive R&D activities and the entry of novel potential therapies. The market is anticipated to grow significantly by 2034, offering promising opportunities for companies in the pharmaceutical industry.
[1] DelveInsight. (2023). Osteosarcoma Market Report 2034. [online] Available at: https://www.delveinsight.com/report-store/osteosarcoma-market
[3] DelveInsight. (2023). Osteosarcoma Pipeline Insight, 2023. [online] Available at: https://www.delveinsight.com/report-store/osteosarcoma-pipeline-insight-2023
){kind=link}